刊物主题:Biomedicine Pharmacology and Toxicology Pharmacy Biochemistry Medical Law Biomedical Engineering
出版者:Springer Netherlands
ISSN:1573-904X
卷排序:33
文摘
PurposeLarger surface area for drug incorporation and superior optical activity makes reduced graphene oxide (rGO) a suitable drug carrier for combination chemotherapeutics delivery. And folate receptors are potential mediators for cancer targeted delivery. This study mainly aimed to prepare irinotecan (IRI)- and docetaxel (DOC)-loaded, folate (FA)-conjugated rGO (FA-P407-rGO/ID) for synergistic cancer therapy.